President Trump appears to want greater user-fee contributions from FDA-regulated industries to offset cuts to federal spending in fiscal 2018. His recently released budget blueprint could complicate negotiations that cosmetics stakeholders were hoping to join, but it also could signal opportunity for an industry seeking increased regulation – and willing to pay for it.
President Donald Trump’s budget outline for fiscal 2018 could throw a monkey wrench in the FDA user-fee reauthorization process currently underway, which in turn could deprive the cosmetics industry of a promising opportunity to fast-track regulatory reform.
The administration’s “America First” fiscal blueprint released March 16 includes only a high-level look at the president’s plans...
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
